These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38863976)

  • 1. Chinese herbal medicine Shufeng Jiedu capsule for mild to moderate COVID-19: a multicenter, randomized, double-blind, placebo-controlled phase II trial.
    Lu CL; Yang LQ; Jin XY; Friedemann T; Li YF; Liu XH; Chen XY; Zou XY; Zhang BR; Wang FX; Lin YL; Tang YM; Cao ML; Jiang YL; Gao YF; Liu K; Tao ZG; Robinson N; Schröder S; Liu JP; Lu HZ
    Front Pharmacol; 2024; 15():1383831. PubMed ID: 38863976
    [No Abstract]   [Full Text] [Related]  

  • 2. Shufeng Jiedu capsule for acute exacerbation of chronic obstructive pulmonary disease: a protocol of multicentre, randomised, double-blind, placebo-controlled trial.
    Xia R; Fei Y; Zhang L; Jie Z; Fan X; Dai M; Moore M; Willcox M; Hu X; Francis N; Liang C; Fei G; Liu J
    BMJ Open; 2023 Sep; 13(9):e070864. PubMed ID: 37775286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The add-on effect of Shufeng Jiedu capsule for treating COVID-19: A systematic review and meta-analysis.
    Sheng X; Chen C; Jiang G; Ji Z; Guo Z; Hu H; Wang H; Zhai J; Zhang D; Zhang J; Guo L
    Front Med (Lausanne); 2022; 9():1020286. PubMed ID: 36325392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chinese Patent Medicine Shufeng Jiedu Capsules as an Adjuvant Therapy for Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    Zhang XW; Xia RY; Gao JQ; Liu JJ; Xu DH; Li X; Hu XY; Willcox M; Moore M; Dai MY; Trill J; Fei YT; Liu JP
    Front Pharmacol; 2022; 13():923395. PubMed ID: 35860018
    [No Abstract]   [Full Text] [Related]  

  • 5. Shufeng Jiedu capsules for treating acute exacerbations of chronic obstructive pulmonary disease: a systematic review and meta-analysis.
    Xia RY; Hu XY; Fei YT; Willcox M; Wen LZ; Yu MK; Zhang LS; Dai MY; Fei GH; Thomas M; Francis N; Wilkinson T; Moore M; Liu JP
    BMC Complement Med Ther; 2020 May; 20(1):151. PubMed ID: 32448238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treating acute exacerbations of COPD with Chinese herbal medicine to aid antibiotic use reduction (Excalibur): a randomised double-blind, placebo-controlled feasibility trial.
    Willcox ML; Hu XY; Oliver T; Thorne K; Boxall C; He G; Simpson C; Brotherwood B; O'Neil A; Waugh R; Tilt E; Trill J; Goward N; Francis N; Thomas M; Little P; Wilkinson T; Liu JP; Griffiths G; Moore M
    Front Pharmacol; 2023; 14():1221905. PubMed ID: 37818189
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy and safety of Regan Syrup in treatment of common cold (wind-heat syndrome):a multicenter, randomized, double-blind, double-dummy, placebo and positive drug-controlled, parallel, phase Ⅱb clinical trial].
    Hu YM; Liu QQ; Chen S; Chen YY; Wang L; Liu N; Chen N; Long YY; Dong H
    Zhongguo Zhong Yao Za Zhi; 2023 Apr; 48(8):2233-2240. PubMed ID: 37282911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploration of the utility of different doses of Qingfei Dayuan granules: a multicenter, randomized, double-blind, placebo-controlled trial.
    Zhu X; Li W; Yang Y; Li H; Yang M; Zhang J; Li X; Yan G; Wu X; Zhao W; Cui M; Yang X; Hu X; Huang J; Ba Y
    Aging (Albany NY); 2024 Feb; 16(5):4503-4517. PubMed ID: 38412322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating Acute EXacerbations of COPD with Chinese HerbAL MedIcine to aid AntiBiotic Use Reduction (EXCALIBUR): study protocol of a randomised double-blind, placebo-controlled feasibility trial.
    Hu XY; Oliver T; Willcox M; Simpson C; Thorne K; Trill J; Francis N; Stuart B; Thomas M; Little P; Liu JP; Griffiths G; Moore M
    Pilot Feasibility Stud; 2022 Dec; 8(1):262. PubMed ID: 36536462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chinese patent herbal medicine (Shufeng Jiedu capsule) for acute upper respiratory tract infections: A systematic review and meta-analysis.
    Zhang YY; Xia RY; Liang SB; Hu XY; Dai MY; Li YL; Zhao LY; Moore M; Fei YT; Liu JP
    Integr Med Res; 2021 Sep; 10(3):100726. PubMed ID: 33996460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Systematic review and Meta-analysis of efficacy and safety of Shufeng Jiedu Capsules in treatment of influenza].
    Zhou F; Zhao GZ; Li B; Xu XL; Shi YF; Mao YY; Tian JH; Liu QQ
    Zhongguo Zhong Yao Za Zhi; 2023 Nov; 48(22):6216-6224. PubMed ID: 38114228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Traditional Chinese Medicine, Maxingshigan-Weijing in the management of COVID-19 patients with severe acute respiratory syndrome: A structured summary of a study protocol for a randomized controlled trial.
    Zeng C; Yuan Z; Pan X; Zhang J; Zhu J; Zhou F; Shan Z; Yuan Y; Ye R; Cheng J
    Trials; 2020 Dec; 21(1):1029. PubMed ID: 33357239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.
    González R; García-Otero L; Pons-Duran C; Marbán-Castro E; Goncé A; Llurba E; Gil MDM; Rodríguez-Zambrano MÁ; Chen H; Ramírez M; Bardají A; Menendez C
    Trials; 2020 Jul; 21(1):607. PubMed ID: 32616063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial.
    Maranda B; Labbé SM; Lurquin M; Brabant P; Fugère A; Larrivée JF; Grbic D; Leroux A; Leduc F; Finzi A; Gaudreau S; Swart Y;
    Lancet Infect Dis; 2024 Jan; 24(1):25-35. PubMed ID: 37619584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.